ENTX HealthcareBeta data

Entera Bio Ltd.

$3.05-1.29%

Price as of close on Nov 3, 2026 · Financials updated Nov 4, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: Israel
Market cap: 530.5M USD
Enterprise value: 517.2M USD
Full-time employees: 20

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.46 vs a peer median of 0.63)bigger price swings (beta 1.46 vs peers 0.63)

Ranks #1,082 of 1,157 healthcare companies (bottom 7%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 60% from December 2022 to December 2025.
Entera Bio had 60% more shares at December 2025 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Entera Bio had 60% more shares at December 2025 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Operating margin at a 5-year low. -27450% in 2025, the weakest of the last 5 years.
Entera Bio's operating margin fell to -27450% in 2025, its lowest in the 5 years of filings we have.
Stock-based pay is a large cost. Stock pay was 6548% of revenue in 2025.
Entera Bio paid employees $3M in stock in 2025, 6548% of its $0M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Investment surge. Capital spending 255% of revenue, up from 35% in 2022.
Entera Bio is spending 255% of revenue on facilities and equipment, up from 35% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

StockQuotient Score

23/ 100

Oct 5 23 → Nov 4 23

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Share count up 251.7% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-11.8%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-2.8%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-2.1%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield4.8%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

0/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ 3-yr revenue
▼ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.2991

3-year revenue growth-32.1%

Yahoo Finance · 3 fiscal years to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -3.70Sector median: 0.0584 · MAD: 0.0840

Revenue growth-100.0%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -4.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

4/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-27450.0%

Yahoo Finance · fiscal year to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-87.4%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capital0.0%

Yahoo Finance · trailing 12 monthsReported value33% base weight · Z-score -0.47Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-138.9%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.46

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -2.46Sector median: 0.6250 · MAD: 0.3380

Current ratio8.98×

Yahoo FinanceReported value33% base weight · Z-score 4.62Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.06×

Yahoo FinanceReported value33% base weight · Z-score 0.80Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Entera Bio

Is Entera Bio getting weaker?: Its latest SEC filing (Oct 14, 2026) got weaker in some ways: share count up 251.7%. Its overall score is unchanged at 23/100 since Oct 28, 2026.
How is Entera Bio valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -11.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.8% vs peers 1.5% (weaker than 100% of peers).
Is Entera Bio growing?: More slowly than most of its peers. Growth scores 0/100 against 1,393 healthcare peers. 3-year revenue growth -32.1% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -32.1% vs peers 5.8% (weaker than 100% of peers).
How profitable is Entera Bio?: Less profitable than most of its peers. Profitability scores 4/100 against 1,393 healthcare peers. Operating margin -27450.0% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -27450.0% vs peers 7.1% (weaker than 100% of peers).
How risky is Entera Bio?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 8.98× vs a peer median of 2.59× (stronger than 85% of peers).Current ratio 8.98× vs peers 2.59× (stronger than 85% of peers). Beta 1.46 vs a peer median of 0.63 (weaker than 86% of peers).Beta 1.46 vs peers 0.63 (weaker than 86% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Oct 14, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Share count up 251.7% (existing holders diluted)

Worth watching: Entera Bio is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	0 USD	0 USD	—
Net income (12 months)	−12.4M USD	−17.0M USD	+37.6%
Free cash flow (12 months)	−9.2M USD	−11.0M USD	+19.7%
Cash	4.1M USD	11.3M USD	+173.4%
Shares outstanding	49.2M	173.1M	+251.7%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	34.7%	24.6%	—	5.0%	0.0%	▼ 5.0 pts
Operating margin	-2139.6%	-9714.2%	—	-5295.6%	-27450.0%	▼ >999 pts
Net margin	-2134.3%	-9754.5%	—	-5271.3%	-27235.7%	▼ >999 pts
Return on assets (ROA)	-46.9%	-99.6%	-75.6%	-101.6%	-71.5%	▲ 30 pts
Return on equity (ROE)	-54.0%	-111.2%	-85.6%	-118.1%	-87.3%	▲ 31 pts
Free cash flow margin	-1590.2%	-9362.7%	—	-3768.5%	-17802.4%	▼ >999 pts
Current ratio	8.01×	9.58×	10.32×	7.63×	6.94×	▼ 9.0%

ENTX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.46 vs a peer median of 0.63)bigger price swings (beta 1.46 vs peers 0.63)

Ranks #1,082 of 1,157 healthcare companies (bottom 7%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 60% from December 2022 to December 2025.

Entera Bio had 60% more shares at December 2025 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Entera Bio had 60% more shares at December 2025 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Operating margin at a 5-year low. -27450% in 2025, the weakest of the last 5 years.

Entera Bio's operating margin fell to -27450% in 2025, its lowest in the 5 years of filings we have.

Stock-based pay is a large cost. Stock pay was 6548% of revenue in 2025.

Entera Bio paid employees $3M in stock in 2025, 6548% of its $0M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Investment surge. Capital spending 255% of revenue, up from 35% in 2022.

Entera Bio is spending 255% of revenue on facilities and equipment, up from 35% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

Questions investors ask about Entera Bio

Is Entera Bio getting weaker?

Its latest SEC filing (Oct 14, 2026) got weaker in some ways: share count up 251.7%. Its overall score is unchanged at 23/100 since Oct 28, 2026.

How is Entera Bio valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -11.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.8% vs peers 1.5% (weaker than 100% of peers).

Is Entera Bio growing?

More slowly than most of its peers. Growth scores 0/100 against 1,393 healthcare peers. 3-year revenue growth -32.1% vs a peer median of 5.8% (weaker than 100% of peers).3-year revenue growth -32.1% vs peers 5.8% (weaker than 100% of peers).

How profitable is Entera Bio?

Less profitable than most of its peers. Profitability scores 4/100 against 1,393 healthcare peers. Operating margin -27450.0% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -27450.0% vs peers 7.1% (weaker than 100% of peers).

How risky is Entera Bio?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 8.98× vs a peer median of 2.59× (stronger than 85% of peers).Current ratio 8.98× vs peers 2.59× (stronger than 85% of peers). Beta 1.46 vs a peer median of 0.63 (weaker than 86% of peers).Beta 1.46 vs peers 0.63 (weaker than 86% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

0 USD

0 USD

—

Net income (12 months)

−12.4M USD

−17.0M USD

+37.6%

Free cash flow (12 months)

−9.2M USD

−11.0M USD

+19.7%

Cash

4.1M USD

11.3M USD

+173.4%

Shares outstanding

49.2M

173.1M

+251.7%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

34.7%

24.6%

—

5.0%

0.0%

▼ 5.0 pts

Operating margin

-2139.6%

-9714.2%

—

-5295.6%

-27450.0%

▼ >999 pts

Net margin

-2134.3%

-9754.5%

—

-5271.3%

-27235.7%

▼ >999 pts

Return on assets (ROA)

-46.9%

-99.6%

-75.6%

-101.6%

-71.5%

▲ 30 pts

Return on equity (ROE)

-54.0%

-111.2%

-85.6%

-118.1%

-87.3%

▲ 31 pts

Free cash flow margin

-1590.2%

-9362.7%

—

-3768.5%

-17802.4%

▼ >999 pts

Current ratio

8.01×

9.58×

10.32×

7.63×

6.94×

▼ 9.0%